HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Gain Therapeutics (NASDAQ: GANX) and maintained a price target of $8 for the stock.